Sustained On- and Off-Treatment Disease Control in Patients With Moderate-to-Severe Atopic Dermatitis Following 12-Week, Open-Label, Once-Daily Abrocitinib 200 mg: A Post Hoc Analysis of the Phase 3 JADE REGIMEN Study. J of Skin [Internet]. 2026 Mar. 10 [cited 2026 Apr. 27];10(2):s732. Available from: https://skin.dermsquared.com/skin/article/view/4025